<DOC>
	<DOCNO>NCT02753803</DOCNO>
	<brief_summary>A randomized , open-label , multiple dosing , three-way crossover clinical trial investigate pharmacokinetic/pharmacodynamic drug-drug interaction evogliptin 5 mg pioglitazone 30 mg oral administration healthy male subject</brief_summary>
	<brief_title>Pharmacokinetic/Pharmacodynamic Drug-drug Interaction Evogliptin 5 mg Pioglitazone 30 mg</brief_title>
	<detailed_description>A randomized , open-label , multiple-dose , three-treatment , three-period , six-sequence , crossover study</detailed_description>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Healthy Male Volunteers ( Age : 19~45years ) 55 &lt; Body Weight &lt; 90 , 18 &lt; BMI &lt; 27 FPG : 70125 mg/dL galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption Clinically significant Medical History Allergy Drug Hypersensitivity AST ( SGOT ) , ALT ( SGPT ) &gt; Upper Normal Range*1.5 , eGFR &lt; 80 mL/min Drink clinical trial period Smoking clinical trial period Grapefruit/Caffeine intake clinical trial period No Contraception</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>